Relapsed/Refractory HER2+Metastatic Breast Cancer

被引：0

作者：

Brufsky, Adam M. ^{[1
]}

Gadi, V. K. ^{[2
]}

Hurvitz, Sara A. ^{[3
]}

Iyengar, Neil M. ^{[4
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA

[2] Univ Illinois, Chicago, IL USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGY-NEW YORK | 2021年 / 35卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：215 / 219

页数：5

共 9 条

[1]

[Anonymous], DS -8201a versus T-DM1 for human epidermal growth factor receptor 2 (HER2)-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and taxane [DESTINY-Breast03]

[2] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].

Awada, Ahmad ;

Colomer, Ramon ;

Inoue, Kenichi ;

Bondarenko, Igor ;

Badwe, Rajendra A. ;

Demetriou, Georgia ;

Lee, Soo-Chin ;

Mehta, Ajay O. ;

Kim, Sung-Bae ;

Bachelot, Thomas ;

Goswami, Chanchal ;

Deo, Suryanarayan ;

Bose, Ron ;

Wong, Alvin ;

Xu, Feng ;

Yao, Bin ;

Bryce, Richard ;

Carey, Lisa A. .

JAMA ONCOLOGY, 2016, 2 (12) :1557-1564

[3] Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial [J].

Lin, Nancy U. ;

Borges, Virginia ;

Anders, Carey ;

Murthy, Rashmi K. ;

Paplomata, Elisavet ;

Hamilton, Erika ;

Hurvitz, Sara ;

Loi, Sherene ;

Okines, Alicia ;

Abramson, Vandana ;

Bedard, Philippe L. ;

Oliveira, Mafalda ;

Mueller, Volkmar ;

Zelnak, Amelia ;

DiGiovanna, Michael P. ;

Bachelot, Thomas ;

Chien, A. Jo ;

O'Regan, Ruth ;

Wardley, Andrew ;

Conlin, Alison ;

Cameron, David ;

Carey, Lisa ;

Curigliano, Giuseppe ;

Gelmon, Karen ;

Loibl, Sibylle ;

Mayor, JoAl ;

McGoldrick, Suzanne ;

An, Xuebei ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) :2610-+

[4] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer [J].

Modi, Shanu ;

Saura, Cristina ;

Yamashita, Toshinari ;

Park, Yeon Hee ;

Kim, Sung-Bae ;

Tamura, Kenji ;

Andre, Fabrice ;

Iwata, Hiroji ;

Ito, Yoshinori ;

Tsurutani, Junji ;

Sohn, Joohyuk ;

Denduluri, Neelima ;

Perrin, Christophe ;

Aogi, Kenjiro ;

Tokunaga, Eriko ;

Im, Seock-Ah ;

Lee, Keun Seok ;

Hurvitz, Sara A. ;

Cortes, Javier ;

Lee, Caleb ;

Chen, Shuquan ;

Zhang, Lin ;

Shahidi, Javad ;

Yver, Antoine ;

Krop, Ian .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) :610-621

[5] Neratinib: the emergence of a new player in the management of HER2+breast cancer brain metastasis [J].

Nasrazadani, Azadeh ;

Brufsky, Adam .

FUTURE ONCOLOGY, 2020, 16 (07) :247-254

[6] End-of-study analysis from the phase Ill, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). [J].

Swain, Sandra M. ;

Miles, David ;

Kim, Sung-Bae ;

Im, Young-Hyuck ;

Im, Seock-Ah ;

Semiglazov, Vladimir ;

Ciruelos, Eva ;

Schneeweiss, Andreas ;

Monturus, Estefania ;

Clark, Emma ;

Knott, Adam ;

Restuccia, Eleonora ;

Benyunes, Mark ;

Cortes, Javier .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[7] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer [J].

Swain, Sandra M. ;

Baselga, Jose ;

Kim, Sung-Bae ;

Ro, Jungsil ;

Semiglazov, Vladimir ;

Campone, Mario ;

Ciruelos, Eva ;

Ferrero, Jean-Marc ;

Schneeweiss, Andreas ;

Heeson, Sarah ;

Clark, Emma ;

Ross, Graham ;

Benyunes, Mark C. ;

Cortes, Javier .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) :724-734

[8] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer [J].

Verma, Sunil ;

Miles, David ;

Gianni, Luca ;

Krop, Ian E. ;

Welslau, Manfred ;

Baselga, Jose ;

Pegram, Mark ;

Oh, Do-Youn ;

Dieras, Veronique ;

Guardino, Ellie ;

Fang, Liang ;

Lu, Michael W. ;

Olsen, Steven ;

Blackwell, Kim .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) :1783-1791

[9] Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives [J].

Wu, Qiuji ;

Liao, Weiting ;

Zhang, Mengxi ;

Huang, Jiaxing ;

Zhang, Pengfei ;

Li, Qiu .

FRONTIERS IN ONCOLOGY, 2020, 10

← 1 →